Industries
Seven kinds of organisation, seven different problems
The science is shared. The problem being solved is not. A Series A biotech and a ministry of health both need validated molecular capability - but almost nothing about how they buy it, fund it or measure it is the same.
Pick yours below.
Pharmaceutical Companies
Discovery capacity without headcount, with the documentation your qualification process expects.
Extend discovery capacity without adding headcountBiotechnology Companies
Board-ready evidence before your next round, with no laboratory of your own.
Board-ready evidence, with no laboratory of your ownDiagnostics Companies
Menu expansion without adding R&D staff - from assay concept to manufacturable, registrable kit.
Menu expansion without adding R&D headcountHospitals & Health Systems
Precision-medicine capability your own team can operate.
Molecular capability your own team can runAcademia & Research Institutes
Industrial-grade analysis and validation your grant depends on.
The analysis and validation your grant depends onGovernment & Public Health
Sovereign capability that stays: trained people, deployed platforms, local manufacturing.
Capability that stays after we leaveEnterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.